News Moderna, Inc.

Stocks

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			After hours 01:00:00
68.27 ^USD	-10.83%		59.86	-12.31%

07-10	US Equity Indexes Rise as Diplomatic Engagements Between Washington, Iran Send Crude Oil Lower	MT
07-10	US Equities Rise, Oil Prices Ease as Trump Confirms Iran Talks	MT

All News

Mentions Relevance

07-09	Moderna wins EU contract for RSV vaccine supply	RE
07-09	Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026	AQ
07-08	Moderna, Inc. Announces Appointment of Michael McDonnell to Board of Directors and Audit Committee, Effective July 8, 2026	CI
07-08	Moderna, Inc. Announces Board and Committee Changes, Effective July 8, 2026	CI
07-08	Moderna Appoints Michael McDonnell to Board of Directors	AQ
07-08	Morgan Stanley Adjusts Price Target Moderna to $39 From $33, Maintains Equalweight Rating	MT
07-07	BofA Adjusts Price Target on Moderna to $38 From $34, Maintains Underperform Rating	MT
07-07	RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating	MT
06-26	Health Care Up on Rotation Into Laggards -- Health Care Roundup	DJ
06-26	Piper Sandler Adjusts Price Target on Moderna to $77 From $69, Maintains Overweight Rating	MT
06-26	Jefferies Adjusts Price Target on Moderna to $53 From $45, Maintains Hold Rating	MT
06-25	Moderna, Inc. - Special Call
06-25	Moderna Science Day Highlights Expanding Potential of mRNA Platform	AQ
06-23	Moderna Receives Unanimous FDA Panel Recommendation for mRNA-Based Influenza Vaccine for Adults 50 and Older	CI
06-22	Leerink Partners Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating	MT
06-19	Oddo BHF Reassured After FDA Decision on Moderna
06-18	Healthcare Stocks Fall on Hawkish Fed Turn -- Healthcare Roundup	DJ
06-18	Moderna Reports Unanimous FDA Panel Backing for Flu Vaccine	MT
06-18	FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine	DJ
06-18	Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine	AQ
06-18	Moderna's Flu Shot Wins Support From FDA Advisers	MT
06-18	Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine
06-18	Moderna wins a favorable FDA panel vote for its mRNA flu vaccine
06-18	US FDA advisers vote in favor of Moderna's flu vaccine	RE
06-18	Moderna's mRNA flu vaccine backed by FDA advisers	RE